KR102087461B1 - 재조합 플라스모디움 팔시파룸 포자소체 단백질의 정제 방법 - Google Patents

재조합 플라스모디움 팔시파룸 포자소체 단백질의 정제 방법 Download PDF

Info

Publication number
KR102087461B1
KR102087461B1 KR1020147033423A KR20147033423A KR102087461B1 KR 102087461 B1 KR102087461 B1 KR 102087461B1 KR 1020147033423 A KR1020147033423 A KR 1020147033423A KR 20147033423 A KR20147033423 A KR 20147033423A KR 102087461 B1 KR102087461 B1 KR 102087461B1
Authority
KR
South Korea
Prior art keywords
days
less
protein
rcsp
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147033423A
Other languages
English (en)
Korean (ko)
Other versions
KR20150027743A (ko
Inventor
제프리 앨렌
그레그 캔틴
리안 헤버스톡
Original Assignee
피페넥스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피페넥스 인크. filed Critical 피페넥스 인크.
Publication of KR20150027743A publication Critical patent/KR20150027743A/ko
Application granted granted Critical
Publication of KR102087461B1 publication Critical patent/KR102087461B1/ko
Assigned to 펠리칸 테크놀로지 홀딩스, 인크. reassignment 펠리칸 테크놀로지 홀딩스, 인크. 권리의 전부이전등록 Assignors: 피페넥스 인크.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020147033423A 2012-05-01 2013-04-22 재조합 플라스모디움 팔시파룸 포자소체 단백질의 정제 방법 Active KR102087461B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261641105P 2012-05-01 2012-05-01
US61/641,105 2012-05-01
US13/844,261 US9169304B2 (en) 2012-05-01 2013-03-15 Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
US13/844,261 2013-03-15
PCT/US2013/037656 WO2013165732A1 (en) 2012-05-01 2013-04-22 Process for purifying recombinant plasmodium falciparum circumsporozoite protein

Publications (2)

Publication Number Publication Date
KR20150027743A KR20150027743A (ko) 2015-03-12
KR102087461B1 true KR102087461B1 (ko) 2020-03-10

Family

ID=49514758

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147033423A Active KR102087461B1 (ko) 2012-05-01 2013-04-22 재조합 플라스모디움 팔시파룸 포자소체 단백질의 정제 방법

Country Status (16)

Country Link
US (2) US9169304B2 (https=)
EP (1) EP2844666B1 (https=)
JP (1) JP6238967B2 (https=)
KR (1) KR102087461B1 (https=)
CN (1) CN104379596B (https=)
AR (1) AR090900A1 (https=)
AU (1) AU2013256757B2 (https=)
BR (1) BR112014027019B1 (https=)
CA (1) CA2870198C (https=)
MX (1) MX352093B (https=)
MY (1) MY166380A (https=)
NZ (1) NZ630121A (https=)
SG (1) SG11201407108TA (https=)
TW (1) TWI630213B (https=)
WO (1) WO2013165732A1 (https=)
ZA (1) ZA201407420B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CA2971151C (en) * 2014-01-09 2020-10-27 Kentucky Bioprocessing, Inc. Method of purifying monoclonal antibodies
CN106459876A (zh) * 2014-03-28 2017-02-22 促接合因子股份有限公司 治疗性细菌的小菌落变异株的制备
CN107532190B (zh) 2014-12-01 2021-07-09 菲尼克斯公司 用于肽生产的融合伴侣
CN109966319B (zh) * 2017-12-22 2022-11-22 四川好医生攀西药业有限责任公司 一种康复新液的原料及其制备方法和应用
CN108559721A (zh) * 2018-05-15 2018-09-21 北京师范大学 一种净化空气的复合微生物菌剂及其应用
EP4171630A1 (en) * 2020-06-29 2023-05-03 Path Pre-erythrocytic malaria vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
WO2012154199A1 (en) 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Soluble recombinant plasmodium falciparum circumsporozoite protein

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2145092B (en) 1983-01-28 1988-04-07 Univ New York Protective peptide antigen
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4830962A (en) 1984-02-09 1989-05-16 Cetus Corporation Recombinant diphtheria toxin fragments
ZA855232B (en) 1984-07-23 1986-02-26 Univ New York Protective peptide antigen corresponding to plasmodium falciparum circumsporozoite protein
NZ213303A (en) 1984-09-12 1988-09-29 Univ New York Plasmodium protein, dna sequence and vaccine
US5178861A (en) 1984-09-12 1993-01-12 New York University Cross-reactive and protective epitopes of circumsporozoite proteins
US4695455A (en) 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4695462A (en) 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8517071D0 (en) 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
EP0229829B1 (en) 1985-07-12 1995-02-22 New York University Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein
CA1340373C (en) 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
EP0252588A3 (en) 1986-05-12 1989-07-12 Smithkline Beecham Corporation Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
FI884485L (fi) 1987-01-30 1988-09-29 Smith Kline Rit Bildning av ytprotein av p. falciparums sporozoit i jaest.
KR0168039B1 (ko) 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5128130A (en) 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
AU625713B2 (en) 1988-02-19 1992-07-16 Microgenesys, Inc. Method for producing recombinant protein derived from the circumsporozoite gene of plasmodium falciparum
US5055294A (en) 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
GB8812214D0 (en) 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5028425A (en) 1988-07-07 1991-07-02 The United States Of America As Represented By The Department Of Health And Human Services Synthetic vaccine against P. falciparum malaria
EP0436597B1 (en) * 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US6043057A (en) 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
JPH03504082A (ja) 1988-12-21 1991-09-12 スミスクライン・バイオロジカルズ 昆虫細胞によるプラスモディウム属サーカムスポロゾイト蛋白の発現
WO1990009444A1 (en) 1989-02-10 1990-08-23 Genesit Oy A method for producing pertussis toxin subunits
US7232671B2 (en) 1989-02-15 2007-06-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
NZ233255A (en) 1989-04-11 1993-02-25 Chiron Corp Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope
ATE127347T1 (de) 1989-04-28 1995-09-15 Sclavo Spa Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
US5169760A (en) 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
DE69002817T2 (de) 1989-11-28 1993-12-09 Wellcome Found Vakzine.
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
AU1762092A (en) 1991-04-01 1992-11-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Circumsporozoite protein of plasmodium reichenowi and vaccine for human malaria
US5935580A (en) 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
DE69434000T3 (de) 1993-10-05 2008-11-06 UCB Pharma Ltd., Slough Impfstoffzusammensetzungen
GB9406492D0 (en) 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
US20040214157A1 (en) 1994-06-29 2004-10-28 Simon C. Burton Chromatographic resins and methods for using same
US5652348A (en) 1994-09-23 1997-07-29 Massey University Chromatographic resins and methods for using same
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
US5932714A (en) 1995-02-23 1999-08-03 Connaught Laboratories Limited Expression of gene products from genetically manipulated strains of Bordetella
SE9600590D0 (sv) 1996-02-19 1996-02-19 Pharmacia Biotech Ab Sätt för kromatografisk separation av peptider och nukleinsyra samt ny högaffin jonbytesmatris
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
WO2000049146A1 (en) 1999-02-18 2000-08-24 Rmf Dictagene S.A. Malaria vaccine
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6942866B2 (en) * 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU2001293074A1 (en) 2000-09-25 2002-04-08 Walter Reed Army Institute Of Research Human liver cell line
US7781186B2 (en) 2000-09-25 2010-08-24 The United States Of America As Represented By The Secretary Of The Army Screening methods using normal human liver cell line
US7363166B2 (en) * 2001-03-30 2008-04-22 Council Of Scientific & Industrial Research Computational method for the identification of candidate proteins useful as anti-infectives
SE0104353D0 (sv) 2001-12-19 2001-12-19 Amersham Biosciences Ab Separation method
WO2004041857A2 (en) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20040067880A1 (en) 2002-10-04 2004-04-08 Kuo Macus Tien Prodrug therapy of liver diseases using receptor-mediated delivery of malarial circumsporozoite protein as a carrier
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
AU2003285932A1 (en) 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
US7670631B2 (en) 2003-03-12 2010-03-02 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
US8399217B2 (en) 2003-03-14 2013-03-19 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
WO2005052151A1 (en) 2003-11-19 2005-06-09 Dow Global Technologies Inc. Improved protein expression systems
CA2546157C (en) 2003-11-21 2014-07-22 Dow Global Technolgies Inc. Improved expression systems with sec-system secretion
WO2005063805A1 (en) 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
EP1709170B1 (en) 2004-01-16 2018-02-21 Pfenex Inc. Expression of mammalian proteins in pseudomonas fluorescens
BRPI0513826A2 (pt) 2004-07-26 2010-06-22 Dow Global Technologies Inc processo para expressão de proteìna melhorada através de engenharia de cepa
AU2005277463A1 (en) 2004-08-20 2006-03-02 Kmt Hepatech, Inc. Malarial animal model having a chimeric human liver
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
WO2006088597A2 (en) 2005-01-18 2006-08-24 Walter Read Army Institute Of Research A plasmodium vivax hybrid circumsporozoite protein and vaccine
EP1754717A1 (en) 2005-08-19 2007-02-21 Université de Lausanne Antigenic peptides and their use
AP2008004448A0 (en) 2005-09-30 2008-04-30 Seattle Biomedical Res Inst Plasmodium liver stage antigens
US7749519B2 (en) 2005-12-09 2010-07-06 Kim Lee Sim Unique DNA and polypeptide sequences based on the circumsporozoite protein of Plasmodium vivax
EP2021489A2 (en) 2006-05-30 2009-02-11 Dow Global Technologies Inc. Codon optimization method
EP2468869B1 (en) 2007-01-31 2015-03-18 Pfenex Inc. Bacterial leader sequences for increased expression
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2009114202A2 (en) 2008-03-14 2009-09-17 The United States Of America As Represented By The Secretary Of The Navy Vaccine and immunization method using plasmodium antigen 2
WO2010008764A1 (en) 2008-06-23 2010-01-21 Dow Global Technologies Inc. Pseudomonas fluorescens strains for production of extracellular recombinant protein
US8058407B2 (en) 2008-10-31 2011-11-15 Wyeth Llc Purification of acidic proteins using ceramic hydroxyapatite chromatography
US8063193B2 (en) 2009-03-27 2011-11-22 Abbott Laboratories Nucleotide and amino acid sequences encoding an exported protein 1 derived from Plasmodium vivax and uses thereof
EP2542574B1 (en) 2010-03-04 2017-08-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
EP2385107B1 (en) 2010-05-03 2016-08-24 Institut Pasteur Lentiviral vector based immunological compounds against malaria
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
WO2012154199A1 (en) 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Soluble recombinant plasmodium falciparum circumsporozoite protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biotech Adv.,2:89-101(1994)
J Chromatogr B Biomed Sci Appl.,762(1):77-86(2001.10.5.)

Also Published As

Publication number Publication date
AU2013256757B2 (en) 2017-02-16
BR112014027019A2 (pt) 2017-07-11
MX2014013124A (es) 2015-02-05
JP2015517464A (ja) 2015-06-22
EP2844666A4 (en) 2015-11-04
CN104379596B (zh) 2018-05-29
CA2870198C (en) 2019-12-03
CA2870198A1 (en) 2013-11-07
US20140051841A1 (en) 2014-02-20
NZ630121A (en) 2016-06-24
SG11201407108TA (en) 2014-11-27
AU2013256757A1 (en) 2014-10-30
US9169304B2 (en) 2015-10-27
WO2013165732A1 (en) 2013-11-07
TWI630213B (zh) 2018-07-21
CN104379596A (zh) 2015-02-25
TW201348250A (zh) 2013-12-01
ZA201407420B (en) 2016-10-26
MX352093B (es) 2017-11-08
KR20150027743A (ko) 2015-03-12
JP6238967B2 (ja) 2017-11-29
EP2844666A1 (en) 2015-03-11
AR090900A1 (es) 2014-12-17
BR112014027019B1 (pt) 2022-09-06
US20160051677A1 (en) 2016-02-25
US9849177B2 (en) 2017-12-26
MY166380A (en) 2018-06-25
EP2844666B1 (en) 2019-07-17

Similar Documents

Publication Publication Date Title
KR102087461B1 (ko) 재조합 플라스모디움 팔시파룸 포자소체 단백질의 정제 방법
AU729459B2 (en) Purification of neurotrophins
AU2016382134B2 (en) Peptide tag and tagged protein including same
JP2006517415A5 (https=)
JP2010534690A (ja) 組み換え成長因子タンパク質の最適化した精製方法
JPS63501471A (ja) インタ−フェロンの精製方法
JP2016515396A (ja) ペプチドおよびタンパク質の発現のための方法
De Graaf et al. Purification and Characterization of a Complex between Cloacin and Its Immunity Protein Isolated from Enterobacter cloacae (Clo DF13) Dissociation and Reconstitution of the Complex
WO2003091429A1 (en) Antimicrobial polypeptide and utizliation thereof
CA3085885A1 (en) Protein purification and virus inactivation with alkyl glycosides
Zhou et al. TrxA mediating fusion expression of antimicrobial peptide CM4 from multiple joined genes in Escherichia coli
TWI660042B (zh) 用以製備目標蛋白的表現構建體與方法
US5561221A (en) Methods and compositions for promoting protein folding
KR101527528B1 (ko) 가용성 재조합 단백질의 생산, 추출 및 정제 방법
CN108752455B (zh) 一种真菌防御素的重组制备方法及其应用
JP2001510848A (ja) フォルダーゼ（ｆｏｌｄａｓｅ）およびシャペロンを用いるリフォールディング方法
Chi et al. Expression of glutathione S-transferase-cardiotoxin fusion protein in Escherichia coli
Asante-Appiah et al. Purification of untagged retroviral integrases by immobilized metal ion affinity chromatography
WO2012115640A1 (en) Liquid insulin- containing compositions and methods of making the same
WO2019210845A1 (zh) 生物活性重组人hnp-1蛋白及应用
KR102011291B1 (ko) 신규한 융합 폴리펩타이드 및 이를 이용하여 인간 부갑상선 호르몬 1-34를 생산하는 방법
WO2008024311A2 (en) Purification of low-abundant recombinant proteins from cell culture
US20220227805A1 (en) Methods of purifying charge-shielded fusion proteins
WO2024263059A1 (ru) Гибридные белки-предшественники пептидных иммуногенов ‒ компонентов вакцины против covid-19

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180420

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190611

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20191210

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200304

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200304

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230117

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250219

Start annual number: 6

End annual number: 6